Mebanazine: Difference between revisions
CSV import |
CSV import |
||
| Line 34: | Line 34: | ||
{{Pharma-stub}} | {{Pharma-stub}} | ||
{{Medicine-stub}} | {{Medicine-stub}} | ||
<gallery> | |||
File:Mebanazine structure.svg|Mebanazine | |||
</gallery> | |||
<gallery> | <gallery> | ||
File:Mebanazine structure.svg|Mebanazine | File:Mebanazine structure.svg|Mebanazine | ||
</gallery> | </gallery> | ||
Revision as of 01:51, 20 February 2025
Mebanazine is a pharmaceutical drug that belongs to the class of antipsychotic medications. It was developed in the mid-20th century and has been used in the treatment of various mental disorders.
History
Mebanazine was first synthesized in the 1950s as part of a series of compounds designed to treat psychosis. It was one of the first antipsychotic drugs to be developed, following the discovery of chlorpromazine in the early 1950s.
Pharmacology
Mebanazine works by blocking dopamine receptors in the brain. Dopamine is a neurotransmitter that plays a key role in mood, motivation, and reward. By blocking these receptors, Mebanazine can help to reduce the symptoms of psychosis.
Clinical Use
Mebanazine has been used in the treatment of a variety of mental disorders, including schizophrenia, bipolar disorder, and severe depression. It is typically used in cases where other treatments have been ineffective.
Side Effects
Like all antipsychotic drugs, Mebanazine can cause a range of side effects. These can include drowsiness, dizziness, and blurred vision. In rare cases, it can also cause more serious side effects such as tardive dyskinesia, a condition characterized by involuntary movements of the face and body.
See Also
References
<references />
-
Mebanazine
-
Mebanazine

